Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency - Abstract

Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.

Written by:
Lee RT¹, Bamberger M², Ellsworth P³   Are you the author?
¹University of Massachusetts Medical School, Worcester, MA, USA. ²UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA. ³Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Reference: Res Rep Urol. 2013 Oct 25;5:147-157
doi: 10.2147/RRU.S38792

PubMed Abstract
PMID: 24400246

UroToday.com Overactive Bladder (OAB) Section